Founded in 2015, our clinical-stage partner is pioneering first-in-class, small molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Their therapies have the potential for profound therapeutic benefit in several difficult-to-treat diseases.

This critical hire was the point person for strategic and executional leadership of the development of our partner’s pipeline. They interfaced with both internal and external stakeholders and oversaw clinical science input for completion and submission of regulatory filings and other regulatory documentation across multiple indications and modalities. This hire also built their team, as well as managed and coached direct reports.